{{Rsnum
|rsid=312481
|Gene=CACNA1D
|Chromosome=3
|position=53517875
|Orientation=minus
|GMAF=0.1823
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CACNA1D
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 54.0 | 38.9 | 7.1
| HCB | 66.4 | 30.5 | 3.1
| JPT | 79.8 | 19.3 | 0.9
| YRI | 80.1 | 17.7 | 2.1
| ASW | 82.1 | 14.3 | 3.6
| CHB | 66.4 | 30.5 | 3.1
| CHD | 0.0 | 0.0 | 0.0
| GIH | 68.7 | 26.3 | 5.1
| LWK | 72.2 | 22.2 | 5.6
| MEX | 56.4 | 41.8 | 1.8
| MKK | 70.3 | 26.5 | 3.2
| TSI | 51.5 | 46.5 | 2.0
| HapMapRevision=28
}}
[[rs312481]] is a SNP in the calcium channel, voltage-dependent, L type, alpha 1D subunit [[CACNA1D]] gene.

A study of 161 Japanese patients (85 men, 76 women) being treated for [[hypertension]] with L-type dCCBs ([[calcium channel blocker]]s) concluded that individuals with [[rs312481]](C;C) genotypes responded better, as measured by lowered systolic and diastolic blood pressure readings.{{PMID|19225208}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}